MediWound's earnings call presented both significant progress and challenges. Highlights included strong progress in clinical trials, partnerships, and revenue growth in the U.S. market for NexoBrid. However, the company faced increased net loss and higher expenses affecting financial performance. Despite these challenges, strategic advancements and collaborations position MediWound for future growth.

Company Guidance

During the MediWound Second Quarter 2025 Earnings Conference Call, the company provided comprehensive guidance on its ongoing and forthcoming projects. Key updates included the active enrollment of patients in the EscharEx VALUE Phase III trial, targeting 216 patients across 40 sites, with an expected interim sample size assessment by mid-2026. The company has established new collaborations with leading wound care companies such as Convatec and Essity to support the VALUE and planned DFU trials. Additionally, MediWound reported a 52% year-over-year revenue growth for NexoBrid in the U.S., driven by increased hospital unit orders and the number of ordering centers. The commissioning of a new manufacturing facility is on track for completion by year-end, with regulatory approvals expected in the first and second halves of 2026 for EMA and FDA, respectively. Financially, MediWound's second-quarter revenue was $5.7 million, a 43% sequential increase, while net loss was $13.3 million, impacted by noncash financial expenses. The company reported $32.9 million in cash and equivalents as of June 30, 2025, with potential proceeds of up to $32 million from Series A warrants. MediWound's strategic focus remains on advancing the EscharEx trial, completing the manufacturing scale-up, and building global recognition through clinical collaborations and publications.

EscharEx VALUE Phase III Trial Progress

The EscharEx VALUE Phase III trial is actively enrolling patients, with plans to enroll 216 patients across 40 sites in the U.S. and Europe. New collaborations with Convatec and Essity support the ongoing VLU trial and planned DFU trial.

NexoBrid U.S. Market Expansion

NexoBrid continues to gain traction in the U.S. market, with a reported 52% year-over-year revenue growth driven by increased hospital unit orders and the number of ordering centers.

Financial Growth in Q2 2025

Second quarter revenue grew 43% sequentially, with total revenue reaching $5.7 million, up from $5.1 million in Q2 2024. Gross profit was $1.3 million or 23.5% of revenue, compared to $0.4 million or 8.8% in the prior year.

Additional Funding from U.S. Department of Defense

MediWound was awarded an additional $3.6 million in non-dilutive funding from the U.S. Department of Defense, bringing total program funding to $18.2 million for a room temperature-stable formulation of NexoBrid.

Strong Cash Position

As of June 30, 2025, MediWound had $32.9 million in cash, cash equivalents, and deposits, providing financial flexibility to advance key programs.

Mediwound (MDWD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MDWD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.81 / -	-0.98	―	―	―
Aug 14, 2025	2025 (Q2)	-0.57 / -1.23	-0.68	-80.88% (-0.55)	―
May 21, 2025	2025 (Q1)	-0.66 / -0.07	-1.05	93.33% (+0.98)	―
Mar 19, 2025	2024 (Q4)	-0.58 / -0.36	-0.19	-89.47% (-0.17)	―
Nov 26, 2024	2024 (Q3)	-0.48 / -0.98	-0.24	-308.33% (-0.74)	―
Aug 14, 2024	2024 (Q2)	-0.42 / -0.68	0.1	-780.00% (-0.78)	―
May 29, 2024	2024 (Q1)	-0.41 / -1.05	-0.44	-138.64% (-0.61)	―	―
Mar 21, 2024	2023 (Q4)	-0.26 / -0.19	-1.18	83.90% (+0.99)	―
Nov 21, 2023	2023 (Q3)	-0.44 / -0.24	-0.91	73.63% (+0.67)	―
Aug 15, 2023	2023 (Q2)	-0.41 / 0.10	-0.91	110.99% (+1.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MDWD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$18.75	$18.57	-0.96%
May 21, 2025	$20.87	$19.89	-4.70%
Mar 19, 2025	$19.27	$18.28	-5.14%
Nov 26, 2024	$17.33	$16.90	-2.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Mediwound (MDWD) report earnings?

Mediwound (MDWD) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is Mediwound (MDWD) earnings time?

Mediwound (MDWD) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MDWD EPS forecast?

MDWD EPS forecast for the fiscal quarter 2025 (Q3) is -0.81.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing